
Despite market volatility, the biotech sector has performed relatively well as a result of breakthrough achievements, advancements in biopharma, and inelastic demand for healthcare products and services.
So, despite the near-term challenges, we think adding quality biotech stocks Pfizer Inc. (PFE) and AstraZeneca PLC (AZN) could be wise now.